Evolving Strategies in EGFR-Mutated NSCLC: Optimizing CNS Control and Managing Treatment-Related Toxicities

This Around the Practice discussion series, Evolving Strategies in EGFR-Mutated NSCLC: Optimizing CNS Control and Managing Treatment-Related Toxicities, brings together leading experts Misako Nagasaka, MD, PhD; Luis Raez, MD; Edgardo Santos, MD, FACP, FASCO; and Jun Zhang, MD, PhD, to explore the newest data and clinical approaches in treating EGFR-mutated non–small cell lung cancer. Through real-world cases, the panel examines how dual EGFR-MET pathway inhibition, exemplified by amivantamab plus lazertinib, is reshaping frontline therapy, central nervous system management, and sequencing beyond progression. The dialogue emphasizes proactive toxicity prevention, multidisciplinary care, and individualized strategies to improve patient outcomes, long-term survival, and quality of life